Report from the MHRA Patient Forum on Biomodifying Technologies January 2020

This is a report on a Patient Forum jointly hosted by the UK Medicines and Healthcare products Regulatory Agency (MHRA) and the ESRC-funded Biomodifying technologies project. The Forum was hosted in January 2020. The report details the purpose of the forum, and reports on the topics of the forum: the potential clinical applications of 'biomodifying technologies' such as gene editing, 3D bioprinting and induced pluripotent stem cells, issues of risk and uncertainty, personalised or customised treatments, and long-term follow up care for patients treated with these novel medicines. The report also details the discussions with forum participants, who included independent patent representatives, representatives of patient organisations and charities, and members of different departments within the MHRA.Funding the for Biomodifying technologies project, of which this report is a part, was provided by the UK Economic and Social Research Council, through grant number ES/P002943/1. The Biomodifying technologies patient forum event was hosted and jointly organised by the UK Medicines and Healthcare products Regulatory Agency